tumorsMalignant tumoursMalignant tumours2224-50572587-6813Rosoncoweb10.18027/2224-5057-2017-2-76-82tumors-346Research ArticleОБЗОРЫ И АНАЛИТИКАREVIEWS AND ANALYSISМетформин в лечении рака молочной железыMetformin in breast cancer treatmentОсиповМ. А.OsipovM. A.

лаборант-исследователь отдела инновационных методов терапевтической онкологии и реабилитации

MD, assistant-researcher at the Department of Innovative Methods of Therapeutic Oncology and Rehabilitation

ocipovmixail@mail.ruСемиглазоваТ. Ю.SemiglazovaT. U.

д.м.н., заведующая отделом инновационных методов терапевтической онкологии и реабилитации

MD, PhD, DSc, leading researcher, Head of Department of Innovative Methods of Therapeutic Oncology and Rehabilitation

tsemiglazova@mail.ruКриворотькоП. В.KrivorotkoP. V.

д.м.н., заведующий отделением опухолей молочных желез

MD, PhD, DSc, Head of Department of Breast Tumors

dr.krivorotko@mail.ruКлименкоВ. В.KlimenkoV. V.

к.м.н., врач-онколог

MD, PhD, medical oncologist

veronika30081987@mail.ruКосторовВ. А.KostorovV. A.

аспирант отдела инновационных методов терапевтической онкологии и реабилитации

MD, postgraduate

kostorov@yandex.ruСемиглазовВ. В.SemiglazovV. V.

д.м.н., ведущий научный сотрудник

MD, PhD, DSc, leading researcher

ssemiglazova@mail.ruЦырлинаЕ. В.TsyrlinaE. V.

к.м.н., ведущий научный сотрудник лаборатории онкоэндокринологии

MD, PhD, leading researcher, Laboratory of Oncoendocrinology

evg.tsyrlina@gmail.comПоповичИ. Г.PopovichI. G.

д.б.н., ведущий научный сотрудник отдела канцерогенеза и онкогеронтологии

veronika30081987@mail.ru

D, PhD, DSc, leading researcher, Department of Carcinogenesis and Oncogerontology

irina_popovich@inbox.ruАнисимовВ. Н.AnisimovV. N.

чл.-корр. РАН, д.м.н., профессор, заведующий отделом канцерогенеза и онкогеронтологии

MD, PhD, DSc, Professor, corresponding member of the Academy of Sciences of Russia, Head of Department of Carcinogenesis and Oncogerontology

aging@mail.ruСемиглазовВ. Ф.SemiglazovV. F.

чл.-корр. РАН, д.м.н., профессор, заведующий научного отдела опухолей репродуктивной системы

MD, PhD, DSc, Professor, corresponding member of the Academy of Sciences of Russia, Head of Scientific Department of tumors of reproductive system

vsemiglazov@mail.ruБерштейнЛ. М.BersteinL. M.

д.м.н., профессор, главный научный сотрудник лаборатории онкоэндокринологии

MD, PhD, DSc, Professor, Principal Researcher Laboratory of Oncoendocrinology

levmb@endocrin.spb.ruФГБУ «Научно-исследовательский институт онкологии имени Н. Н. Петрова», Санкт-ПетербургРоссияN. N. Petrov Research Institute of Oncology, Saint PetersburgRussian Federation201720072017027682Copyright © Осипов М.А., Семиглазова Т.Ю., Криворотько П.В., Клименко В.В., Косторов В.А., Семиглазов В.В., Цырлина Е.В., Попович И.Г., Анисимов В.Н., Семиглазов В.Ф., Берштейн Л.М., 20172017Осипов М.А., Семиглазова Т.Ю., Криворотько П.В., Клименко В.В., Косторов В.А., Семиглазов В.В., Цырлина Е.В., Попович И.Г., Анисимов В.Н., Семиглазов В.Ф., Берштейн Л.М.Osipov M.A., Semiglazova T.U., Krivorotko P.V., Klimenko V.V., Kostorov V.A., Semiglazov V.V., Tsyrlina E.V., Popovich I.G., Anisimov V.N., Semiglazov V.F., Berstein L.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.malignanttumors.org/jour/article/view/346

В обзоре освещены клинические исследования, посвященные эффективности метформина при раке молочной железы (РМЖ). Согласно результатам ряда работ когортного и «случай-контроль» типа, применение метформина на фоне комплексного лечения больных РМЖ приводит к увеличению безрецидивной и общей выживаемости. В скором времени ожидаются первые публикации рандомизированных клинических исследований метформина на фоне неоадъювантного и адъювантного лечения больных РМЖ. 

Clinical trials of metformin efficacy in breast cancer were reviewed in this article. According to some data from cohort and case-controlled studies, the use of metformin with combined therapy of breast cancer improves overall and disease-free survival. Initial data from randomized clinical trials of metformin in adjuvant and neoadjuvant therapy of breast cancer are expected in the nearest future. 

рак молочной железыметформинхимиотерапиягормонотерапияклинические исследованияbreast cancermetforminchemotherapyhormonal therapyclinical trialsReferencesBerstein L.M. Antidiabetic biguanide metformin and cancer incidence, Diabetes mellitus, 2010, Vol. 3, pp. 45–48.Berstein L.M. Antidiabetic biguanide metformin and cancer incidence, Diabetes mellitus, 2010, Vol. 3, pp. 45–48.Berstein L.M., Vasilyev D. A., Iyevleva A.G. et al. Potential and real ‘antineoplastic’ and metabolic effect of metformin in diabetic and nondiabetic postmenopausal females, Future Oncol., 2015, Vol. 11, No. 5, pp. 759–70.Berstein L.M., Vasilyev D. A., Iyevleva A.G. et al. Potential and real ‘antineoplastic’ and metabolic effect of metformin in diabetic and nondiabetic postmenopausal females, Future Oncol., 2015, Vol. 11, No. 5, pp. 759–70.Dilman V.M., Sofronov V.N., Anisimov V.N. et al. elimination of phenformin immunosuppression caused by 1,2 – dimethylhydrazine in rats, Probl. in Onc., 1977, Vol. 23, No. 8, pp. 50–54.Dilman V.M., Sofronov V.N., Anisimov V.N. et al. elimination of phenformin immunosuppression caused by 1,2 – dimethylhydrazine in rats, Probl. in Onc., 1977, Vol. 23, No. 8, pp. 50–54.Dilman V.M., Anisimov V.N., Effect of treatment with phenformin, diphenylhydantoin or L-DOPA on life span and tumor incidence in C3H/Sn mice, Gerontology, 1980, Vol. 26, pp. 241–246.Dilman V.M., Anisimov V.N., Effect of treatment with phenformin, diphenylhydantoin or L-DOPA on life span and tumor incidence in C3H/Sn mice, Gerontology, 1980, Vol. 26, pp. 241–246.Dilman V.M., Berstein L.M., Yevtushenko T. P. et al. Preliminary evidence on metabolic rehabilitation in cancer patients, Arch. Geschwulstforsch., 1988, Vol. 58, pp. 175–183.Dilman V.M., Berstein L.M., Yevtushenko T. P. et al. Preliminary evidence on metabolic rehabilitation in cancer patients, Arch. Geschwulstforsch., 1988, Vol. 58, pp. 175–183.Dilman V.M., Berstein L.M., Zabezhinski M. A. et al. Inhibition of DMBA-induced carcinogenesis by phenformin in the mammary gland of rats, Arch. Geschwulstforsch, 1978, Vol. 48, pp. 1–8.Dilman V.M., Berstein L.M., Zabezhinski M. A. et al. Inhibition of DMBA-induced carcinogenesis by phenformin in the mammary gland of rats, Arch. Geschwulstforsch, 1978, Vol. 48, pp. 1–8.Anisimov V.N. Influence of Buformin and diphenin on life span, estrous function and frequency of spontaneous tumors in female rats, Probl. in Onc., 1980, Vol. 26, No. 6.Anisimov V.N. Influence of Buformin and diphenin on life span, estrous function and frequency of spontaneous tumors in female rats, Probl. in Onc., 1980, Vol. 26, No. 6.Anisimov V.N., Alexandrov V.A., Belous N.M., Vasileva I.A. Buformin inhibit transplacental blastomogenic effect of nitrosomethylurea in rrats, Bull. of Exp. Biol. and Med., 1980, Vol 89, No. 7, pp. 88–90.Anisimov V.N., Alexandrov V.A., Belous N.M., Vasileva I.A. Buformin inhibit transplacental blastomogenic effect of nitrosomethylurea in rrats, Bull. of Exp. Biol. and Med., 1980, Vol 89, No. 7, pp. 88–90.Anisimov V.N., Belous N.M., Vasileva I. A., Dilman V.M. Phenformin inhibits of mammary tumor development induced by of N – nitrosomethylurea in rats, Exp. Onc., 1980, Vol. 2, No. 3, pp. 40–43.Anisimov V.N., Belous N.M., Vasileva I. A., Dilman V.M. Phenformin inhibits of mammary tumor development induced by of N – nitrosomethylurea in rats, Exp. Onc., 1980, Vol. 2, No. 3, pp. 40–43.Alexandrov V., Anisimov V., Belous N. et al. The inhibition of the transplacental blastomogenic effect of nitrosomethylurea by postnatal administration of buformin to rats, Carcinogenesis, 1980, Vol. 1, pp. 975–978.Alexandrov V., Anisimov V., Belous N. et al. The inhibition of the transplacental blastomogenic effect of nitrosomethylurea by postnatal administration of buformin to rats, Carcinogenesis, 1980, Vol. 1, pp. 975–978.Anisimov V.N. Do metformin a real anticarcinogen? A critical reapraisal of experimental data, Ann. Transl. Med., 2014, Vol. 2, No. 6, p. 60. doi: 10.3978/j. issn. 2305-5839.2014.06.02.Anisimov V.N. Do metformin a real anticarcinogen? A critical reapraisal of experimental data, Ann. Transl. Med., 2014, Vol. 2, No. 6, p. 60. doi: 10.3978/j. issn. 2305-5839.2014.06.02.Anisimov V.N. Metfomin for cancer and aging prevention: is it a time to make the long story short? Oncotarget, 2015, Vol. 6, No. 37, pp. 39398–39407. doi: 10.18632/oncotarget. 6347.Anisimov V.N. Metfomin for cancer and aging prevention: is it a time to make the long story short? Oncotarget, 2015, Vol. 6, No. 37, pp. 39398–39407. doi: 10.18632/oncotarget. 6347.Chan A. T. Metformin for cancer prevention: a reason for optimism, Lancet Oncol., 2016, Vol. 17, No. 4., pp. 407–409. doi: 10.1016/S1470–2045 (16) 00006-1.Chan A. T. Metformin for cancer prevention: a reason for optimism, Lancet Oncol., 2016, Vol. 17, No. 4., pp. 407–409. doi: 10.1016/S1470–2045 (16) 00006-1.Bolin L., Zeying F., Susan M. et al. Metformin induces unique biological and molecular responses in triple negative breast cancer cells, Cell Cycle, 2009, Vol. 8, pp. 2031–2040.Bolin L., Zeying F., Susan M. et al. Metformin induces unique biological and molecular responses in triple negative breast cancer cells, Cell Cycle, 2009, Vol. 8, pp. 2031–2040.Cheong J. Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin. Is effective against a broad spectrum of preclinical cancer models, Mol. Cancer Therap., 2011, Vol. 10, No. 12, pp. 2350–2362.Cheong J. Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin. Is effective against a broad spectrum of preclinical cancer models, Mol. Cancer Therap., 2011, Vol. 10, No. 12, pp. 2350–2362.Phoenix K., Vumbaca F., Claffey K. Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model, Breast Cancer Res. Treat., 2008, Vol. 113, pp. 101–111.Phoenix K., Vumbaca F., Claffey K. Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model, Breast Cancer Res. Treat., 2008, Vol. 113, pp. 101–111.Ilipoulos D., Hirsch H. A., Struhl K. Metformin decreases the doses of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types, Cancer Res., 2011, Vol. 71, pp. 3196–3201.Ilipoulos D., Hirsch H. A., Struhl K. Metformin decreases the doses of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types, Cancer Res., 2011, Vol. 71, pp. 3196–3201.Hirsch H., Iliopoulos D., Struhl K. Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth, Proc. Natl. Acad. Sci. USA., 2013, Vol. 110, pp. 972–977.Hirsch H., Iliopoulos D., Struhl K. Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth, Proc. Natl. Acad. Sci. USA., 2013, Vol. 110, pp. 972–977.Osipov M. A., Semiglazova T.U., Popovich I. G. Efficacy of paclitaxel, metformin, melatonin and their combinations in on the growth of transplantable HER–2 positive breeat tumor in female FVB/N mice, J. Malignant Tumors, 2016, Vol. 4(s), p. 324.Osipov M. A., Semiglazova T.U., Popovich I. G. Efficacy of paclitaxel, metformin, melatonin and their combinations in on the growth of transplantable HER–2 positive breeat tumor in female FVB/N mice, J. Malignant Tumors, 2016, Vol. 4(s), p. 324.Wang Y., Wei J., Li L. et al. Combined use of metformin and everolimus is synergistic in the treatment of breast cancer cells, Oncol. Res., 2015, Vol. 22, No. 4, pp. 193–201.Wang Y., Wei J., Li L. et al. Combined use of metformin and everolimus is synergistic in the treatment of breast cancer cells, Oncol. Res., 2015, Vol. 22, No. 4, pp. 193–201.Zhuang Y., Miskimins W. Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1, J. Mol. Signal, 2008, Vol. 3, pp. 18.Zhuang Y., Miskimins W. Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1, J. Mol. Signal, 2008, Vol. 3, pp. 18.Lau Y., Du X., Rayannavar V. Metformin and erlotinib synergize to inhibit basal breast cancer, Oncotarget, 2014, Vol. 5, No. 21, pp. 10503–17.Lau Y., Du X., Rayannavar V. Metformin and erlotinib synergize to inhibit basal breast cancer, Oncotarget, 2014, Vol. 5, No. 21, pp. 10503–17.Berstein L., Yue W., Wang J., Santen R. Isolated and combined action of tamoxifen and metformin in wild-type, tamoxifenresistant, and estrogen-deprived MCF-7 cells, Breast Cancer Res. Treat., 2011, Vol. 128, No. 1, pp. 109–17.Berstein L., Yue W., Wang J., Santen R. Isolated and combined action of tamoxifen and metformin in wild-type, tamoxifenresistant, and estrogen-deprived MCF-7 cells, Breast Cancer Res. Treat., 2011, Vol. 128, No. 1, pp. 109–17.Ashour A., Sayed-Ahmed M., Abd-Allah A. et al. Metformin rescues the myocardium from doxorubicin-induced energy starvation and mitochondrial damage in rats, Oxid. Med. Cel. Longev., 2012, Vol. 17:34195.Ashour A., Sayed-Ahmed M., Abd-Allah A. et al. Metformin rescues the myocardium from doxorubicin-induced energy starvation and mitochondrial damage in rats, Oxid. Med. Cel. Longev., 2012, Vol. 17:34195.Soo J., Ng C., Tan S. et al. Metformin synergizes 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) combination therapy through impairing intracellular ATP production and DNA repair in breast cancer stem cells, Apoptosis, 2015, Vol. 20, No. 10, pp. 1373–87.Soo J., Ng C., Tan S. et al. Metformin synergizes 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) combination therapy through impairing intracellular ATP production and DNA repair in breast cancer stem cells, Apoptosis, 2015, Vol. 20, No. 10, pp. 1373–87.Zhou G., Myers R., Li Y. et al. Role of AMPactivated protein kinase in mechanism of metformin action, J. Clin. Invest., 2001, Vol. 108, No 8, pp. 1167–1174.Zhou G., Myers R., Li Y. et al. Role of AMPactivated protein kinase in mechanism of metformin action, J. Clin. Invest., 2001, Vol. 108, No 8, pp. 1167–1174.Xianbin C., Xi H., Xiaojun T. et al. Metformin Induced AMPK Activation, G0/G1 Phase Cell Cycle Arrest and the Inhibition of Growth of Esophageal Squamous Cell Carcinomas In Vitro and In Vivo, PLoS One, 2015, Vol. 10, No. 7: e0133349.Xianbin C., Xi H., Xiaojun T. et al. Metformin Induced AMPK Activation, G0/G1 Phase Cell Cycle Arrest and the Inhibition of Growth of Esophageal Squamous Cell Carcinomas In Vitro and In Vivo, PLoS One, 2015, Vol. 10, No. 7: e0133349.Shackelford D., Shaw R. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression, Nat. Rev. Cancer, 2009, Vol. 9, No. 8, pp. 563–575.Shackelford D., Shaw R. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression, Nat. Rev. Cancer, 2009, Vol. 9, No. 8, pp. 563–575.Mei P., Kwame O., Darko Т. et al. Combination of Metformin with Chemotherapeutic Drugs via Different Molecular Mechanisms, Cancer Treatment Reviews, 2017. doi: 10.1016/j.ctrv.2017.01.005.Mei P., Kwame O., Darko Т. et al. Combination of Metformin with Chemotherapeutic Drugs via Different Molecular Mechanisms, Cancer Treatment Reviews, 2017. doi: 10.1016/j.ctrv.2017.01.005.Jia Y., Ma Z., Liu X. et al. Metformin prevents DMH-induced colorectal cancer in diabetic rats by reversing the warburg effect of breast cancer cells, Oncol. Res., 2015, Vol. 22, No. 4, pp. 193–201.Jia Y., Ma Z., Liu X. et al. Metformin prevents DMH-induced colorectal cancer in diabetic rats by reversing the warburg effect of breast cancer cells, Oncol. Res., 2015, Vol. 22, No. 4, pp. 193–201.Pierotti M. A., Berrino F., Gariboldi M. et al. Targeting metabolism for cancer treatment and prevention: Metformin, an old drug with multi-faceted effects, Oncogene, 2013, Vol. 32, No. 12, pp. 1475–1487.Pierotti M. A., Berrino F., Gariboldi M. et al. Targeting metabolism for cancer treatment and prevention: Metformin, an old drug with multi-faceted effects, Oncogene, 2013, Vol. 32, No. 12, pp. 1475–1487.Pollak M. Metformin and other biguanides in oncology: advancing the research agenda, Cancer Prev. Res. (Phila), 2010, Vol. 3, Nol. 9, pp. 1060–1065.Pollak M. Metformin and other biguanides in oncology: advancing the research agenda, Cancer Prev. Res. (Phila), 2010, Vol. 3, Nol. 9, pp. 1060–1065.Brown K., Hunger N., Docanto M. Simpson E. Metformin inhibits aromatase expression in human breast adipose stromal cells via stimulation of AMP-activated protein kinase, Breast Cancer Res. Treat., 2010, Vol. 123, pp. 591–596.Brown K., Hunger N., Docanto M. Simpson E. Metformin inhibits aromatase expression in human breast adipose stromal cells via stimulation of AMP-activated protein kinase, Breast Cancer Res. Treat., 2010, Vol. 123, pp. 591–596.Vazquez-Martin A., Oliveras-Ferraros C. Menendez J. A. The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells, Cell Cycle, 2009, Vol. 8, pp. 88–96.Vazquez-Martin A., Oliveras-Ferraros C. Menendez J. A. The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells, Cell Cycle, 2009, Vol. 8, pp. 88–96.Evans J.M., Donnelly L. A., Emslie-Smith A.M. et al. Metformin and reduced risk of cancer in diabetic patients, BMJ, 2005, Vol. 330, pp. 1304–5.Evans J.M., Donnelly L. A., Emslie-Smith A.M. et al. Metformin and reduced risk of cancer in diabetic patients, BMJ, 2005, Vol. 330, pp. 1304–5.Landman G., Kleefstra N., van Hateren G. Metformin associated with lower cancer mortality in type-2 diabetes: ZODIAC – 16, Diabetes care, 2010, Vol. 33, No. 2, pp. 322–326.Landman G., Kleefstra N., van Hateren G. Metformin associated with lower cancer mortality in type-2 diabetes: ZODIAC – 16, Diabetes care, 2010, Vol. 33, No. 2, pp. 322–326.Bosco J., Antonsen S., S rensen H. Metformin and incident breast cancer among diabetic women: a population-based casecontrol study in Denmark, Cancer Epidemiol. Biomarkers Prev., 2011, Vol. 20, No. 1, pp. 101–11.Bosco J., Antonsen S., S rensen H. Metformin and incident breast cancer among diabetic women: a population-based casecontrol study in Denmark, Cancer Epidemiol. Biomarkers Prev., 2011, Vol. 20, No. 1, pp. 101–11.Libby G., Donnely L., Donnan P. et al. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes, Diabetes Care, 2009, Vol. 32, pp. 1620–1625.Libby G., Donnely L., Donnan P. et al. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes, Diabetes Care, 2009, Vol. 32, pp. 1620–1625.Bodmer M., Meier C., Krahenbuhl S. et al. Long-term metformin use is associated with decreased risk of breast cancer, Diabetes Care, 2010, Vol. 33, pp. 1304–8.Bodmer M., Meier C., Krahenbuhl S. et al. Long-term metformin use is associated with decreased risk of breast cancer, Diabetes Care, 2010, Vol. 33, pp. 1304–8.Lega I., Austin P., Gruneir A. et al. Association between metformin therapy and mortality after breast cancer: a population-based study, Diabetes Care, 2013, Vol. 36, pp. 3018–3026.Lega I., Austin P., Gruneir A. et al. Association between metformin therapy and mortality after breast cancer: a population-based study, Diabetes Care, 2013, Vol. 36, pp. 3018–3026.Oppong B., Pharmer L., Oskar S. et al. The effect of metformin on breast cancer outcomes in patients with type 2 diabetes, Cancer Med., 2014, Vol. 3, pp. 1025–1034.Oppong B., Pharmer L., Oskar S. et al. The effect of metformin on breast cancer outcomes in patients with type 2 diabetes, Cancer Med., 2014, Vol. 3, pp. 1025–1034.Bayraktar S., Hernadez-Aya L., Lei X. et al. Effect of metformin on survival outcomes in diabetic patients with triple receptornegative breast cancer, Cancer, 2012, Vol. 118, pp. 1202–1211.Bayraktar S., Hernadez-Aya L., Lei X. et al. Effect of metformin on survival outcomes in diabetic patients with triple receptornegative breast cancer, Cancer, 2012, Vol. 118, pp. 1202–1211.Peeters P., Bazelier M., Vestergaard P. et al. Use of metformin and survival of diabetic women with breast cancer, Curr. Drug Saf., 2013, Vol. 8, pp. 357–63.Peeters P., Bazelier M., Vestergaard P. et al. Use of metformin and survival of diabetic women with breast cancer, Curr. Drug Saf., 2013, Vol. 8, pp. 357–63.He X., Esteva F., Ensor J. et al. Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer, Ann. Oncol., 2012, Vol. 23, pp. 1771–80.He X., Esteva F., Ensor J. et al. Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer, Ann. Oncol., 2012, Vol. 23, pp. 1771–80.Kim H., Kwon H., Lee J. Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes, Breast Cancer Res., 2015, Vol. 17, p. 64.Kim H., Kwon H., Lee J. Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes, Breast Cancer Res., 2015, Vol. 17, p. 64.Семиглазова Т. Ю., Клименко В. В., Филатова Л. В. и др. Маркеры эффективности предоперационной таксансодержащей химиотерапии местнораспространенного рака молочной железы // Вопр. онкологии. 2013. Т. 59. № 3. С. 363–368.Семиглазова Т. Ю., Клименко В. В., Филатова Л. В. и др. Маркеры эффективности предоперационной таксансодержащей химиотерапии местнораспространенного рака молочной железы // Вопр. онкологии. 2013. Т. 59. № 3. С. 363–368.[Semiglazova T. J., Klimenko V. V., Filatova L.V. i dr. Markery effektivnosti predoperatsionnoy taksansoderzhashchey khimioterapii mestnorasprostranennogo raka molochnoy zhelezy, Vopr. onkologii, 2013, Vol. 59, No. 3, pp. 363–368. (In Russ.)].[Semiglazova T. J., Klimenko V. V., Filatova L.V. i dr. Markery effektivnosti predoperatsionnoy taksansoderzhashchey khimioterapii mestnorasprostranennogo raka molochnoy zhelezy, Vopr. onkologii, 2013, Vol. 59, No. 3, pp. 363–368. (In Russ.)].Sao J., Shana L., Sharon H. Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast Cancer, J. Clin. Onc., 2009, Vol. 27, pp. 3297–3302.Sao J., Shana L., Sharon H. Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast Cancer, J. Clin. Onc., 2009, Vol. 27, pp. 3297–3302.Van Der Laat A. Neoadjuvant metformin along with systemic therapy increase pathological complete responses in breast cancer: Results of a cross-sectional study, Hospital Mexico, Costa Rica, J. Clin. Oncol., 2016, Vol. 34, e12519.Van Der Laat A. Neoadjuvant metformin along with systemic therapy increase pathological complete responses in breast cancer: Results of a cross-sectional study, Hospital Mexico, Costa Rica, J. Clin. Oncol., 2016, Vol. 34, e12519.Niraula S., Dowling R., Ennis M. et al. Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study, Breast Cancer Res. Treat., 2012, Vol. 135, No. 3, pp. 821–30.Niraula S., Dowling R., Ennis M. et al. Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study, Breast Cancer Res. Treat., 2012, Vol. 135, No. 3, pp. 821–30.Bonanni B., Puntoni M., Cazzaniga M. et al. Dual Effect of Metformin on Breast Cancer Proliferation in a Randomized Presurgical Trial, J. Clin. Oncol., 2012, Vol. 30, No. 21, pp. 2593–600.Bonanni B., Puntoni M., Cazzaniga M. et al. Dual Effect of Metformin on Breast Cancer Proliferation in a Randomized Presurgical Trial, J. Clin. Oncol., 2012, Vol. 30, No. 21, pp. 2593–600.Hadad S., Iwamoto T., Jordan L. et al. Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial, Breast Cancer Res. Treat., 2011, Vol. 128, No. 3, pp. 783–94.Hadad S., Iwamoto T., Jordan L. et al. Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial, Breast Cancer Res. Treat., 2011, Vol. 128, No. 3, pp. 783–94.Hadad S., Coates. P., Jordan L. et al. Evidence for biological effects of metformin in operable breast cancer: biomarker analysis in a pre-operative window of opportunity randomized trial, Breast Cancer Res. Treat., 2015, Vol. 150, No. 1, pp. 149–55.Hadad S., Coates. P., Jordan L. et al. Evidence for biological effects of metformin in operable breast cancer: biomarker analysis in a pre-operative window of opportunity randomized trial, Breast Cancer Res. Treat., 2015, Vol. 150, No. 1, pp. 149–55.Neoadjuvant FDC With Melatonin or Metformin for Locally Advanced Breast Cancer, ClinicalTrials.gov, Identifier: NCT02506777.Neoadjuvant FDC With Melatonin or Metformin for Locally Advanced Breast Cancer, ClinicalTrials.gov, Identifier: NCT02506777.Neoadjuvant Toremifene With Melatonin or Metformin in Locally Advanced Breast Cancer, ClinicalTrials.gov, Identifier: NCT02506790.Neoadjuvant Toremifene With Melatonin or Metformin in Locally Advanced Breast Cancer, ClinicalTrials.gov, Identifier: NCT02506790.

The authors declare that there are no conflicts of interest present.